參考文獻/References:
[1] LI YC,ZHAO CH,YU ZB,et al.Low expression of miR-381 is a favorite prognosis factor and enhances the chemosensitivity of osteosarcoma[J].Oncotarget,2016,7(42):68585-68596.
[2] 郭會利,郭樹農(nóng),王軍輝,等.氯化鍶注射液治療轉(zhuǎn)移性骨腫瘤的臨床療效觀察[J].中醫(yī)正骨,2014,26(1):70-71.
[3] BOUVIER C,MACAGNO N,NGUYEN Q,et al.Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and beta 1-integrin in conventional osteosarcoma[J].Oncotarget,2016,7(40):64702-64710.
[4] ANDERSON ME.Update on survival in osteosarcoma[J].Orthop Clin North Am,2016,47(1):283-292.
[5] LETTIERI CK,APPEL N,LABBAN N,et al.Progress and opportunities for immune therapeutics in osteosarcoma[J].Immunotherapy,2016,8(10):1233-1244.
[6] 劉小軍.以異常能量代謝為靶點治療惡性腫瘤的研究進展[J].復(fù)旦學(xué)報:醫(yī)學(xué)版,2012,39(6):676-679.
[7] 菅記涌,張勇,朱大海.丙酮酸脫氫酶激酶的研究進展[J].基礎(chǔ)醫(yī)學(xué)與臨床,2008,28(11):1212-1215.
[8] WAKABAYASHI H,SAITO J,TAKI J,et al.Triple-phase contrast-enhanced MRI for the prediction of preoperative chemotherapeutic effect in patients with osteosarcoma:comparison with Tc-99m-MIBI scintigraphy[J].Skeletal Radiol,2016,45(1):87-95.
[9] MA Y,XU W,BAI R,et al.Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary:identification of the best benefited patients[J].Eur J Nucl Med Mol Imaging,2016,44(2):199-205.
[10] 童晶濤.丙酮酸脫氫酶激酶-1在結(jié)腸癌中的表達及在細胞增殖和化療中的作用[D].重慶:第三軍醫(yī)大學(xué),2010.
[11] RICHARD SM,MARIGNAC VL.Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition[J].J Cancer Res Ther,2015,11(2):336-340.
[12] PARK SY,YOON JK,PARK KJ,et al.Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheralnon-small cell lung cancer[J].CancerImaging,2015:21.
[13] 朱明珍,茅國新,蔣華,等.二氯乙酸鈉誘導(dǎo)肺腺癌細胞株A549凋亡的實驗研究[J].現(xiàn)代醫(yī)藥衛(wèi)生,2014,30(3):321-323.
[14] LIU Z,SUN Y,TAN S,et al.Nutrient deprivation-related OXPHOS/glycolysis interconversion via HIF-1α/C-MYC pathway in U251 cells[J].Tumour Biol,2016,37(5):6661-6671.
[15] PRIGIONE A,ROHWER N,HOFFMANN S,et al.HIF1α modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2[J].Stem Cells,2014,32(2):364-376.
相似文獻/References:
[1]羅明星,劉丙根,羅文禮,等.保肢與截肢治療后骨肉瘤患者肢體功能及生活質(zhì)量的Meta分析[J].中醫(yī)正骨,2017,29(07):41.
LUO Mingxing,LIU Binggen,LUO Wenli,et al.Comparison of limb salvage and amputation on limb function and life quality of patients with osteosarcoma:a meta analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(01):41.
[2]丁聚賢,謝興文,許偉,等.中醫(yī)藥在骨肉瘤放化療中的作用研究進展[J].中醫(yī)正骨,2018,30(05):43.
[3]羅漫麗,黃滿玉,李東升,等.多種血清腫瘤相關(guān)抗原自身抗體聯(lián)合檢測對骨肉瘤的診斷價值研究[J].中醫(yī)正骨,2021,33(04):32.
LUO Manli,HUANG Manyu,LI Dongsheng,et al.A study of the clinical value of combined detection on serum autoantibodies against tumor-associated antigens in the diagnosis of osteosarcomas[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2021,33(01):32.
[4]劉柏良,秦瑨,劉小榮,等.miR-27a參與骨肉瘤發(fā)生發(fā)展作用機制的研究進展[J].中醫(yī)正骨,2025,37(03):53.